Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis (original) (raw)

Acquired resistance to echinocandins in Candida albicans: case report and review

Journal of Antimicrobial Chemotherapy, 2007

Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment

Michaela Lackner

Antimicrobial agents and chemotherapy, 2014

View PDFchevron_right

Development of echinocandin resistance in Candida krusei isolates following exposure to micafungin and caspofungin in a BM transplant unit

Micha Srour

Bone marrow transplantation, 2015

View PDFchevron_right

Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations

David Perlin

View PDFchevron_right

Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1

David Perlin

Antimicrobial Agents and Chemotherapy, 2006

View PDFchevron_right

Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin

David Perlin

Pharmacotherapy, 2006

View PDFchevron_right

Quick detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans

David Perlin

Journal of Clinical Microbiology, 2015

View PDFchevron_right

Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

Vidmantas Petraitis

Antimicrobial Agents and Chemotherapy, 2001

View PDFchevron_right

Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

David Perlin

Antimicrobial Agents and Chemotherapy, 2011

View PDFchevron_right

Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin

Eric Dannaoui

Antimicrobial Agents and Chemotherapy, 2013

View PDFchevron_right

In vitro activity of echinocandins against non-Candida albicans: Is echinocandin antifungal activity the same?

Emilia Canton

Enfermedades Infecciosas y Microbiología Clínica, 2011

View PDFchevron_right

Resistance to echinocandin-class antifungal drugs

David Perlin

Drug Resistance Updates, 2007

View PDFchevron_right

Multiple Genes of Candida albicans Influencing Echinocandin Susceptibility in Caspofungin-Adapted Mutants

Anshuman Yadav

Antimicrobial Agents and Chemotherapy

View PDFchevron_right

Correlation between antifungal susceptibility of clinical isolates of Candida albicans to fluconazole and ERG11 mutations

Laura Najvar

View PDFchevron_right

FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy

Isabel Miranda

Antimicrobial Agents and Chemotherapy, 2011

View PDFchevron_right

Resistance to Echinocandins Complicates a Case of Candida albicans Bloodstream Infection: A Case Report

Nicolo musso

Journal of Fungi, 2021

View PDFchevron_right

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

mk vyas

Antimicrobial Agents and Chemotherapy, 2005

View PDFchevron_right

The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

Andrea Kwa

Antimicrobial Agents and Chemotherapy, 2012

View PDFchevron_right

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

David Denning

Journal of Antimicrobial Chemotherapy, 2002

View PDFchevron_right

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Lajos Forgács

Journal of Fungi

View PDFchevron_right

Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates

Aristea Velegraki

Antimicrobial Agents and Chemotherapy, 2013

View PDFchevron_right

Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia

Lai-Chu See

Journal of Microbiology, Immunology and Infection, 2014

View PDFchevron_right

In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -Susceptible Candida glabrata

Katsuhiko Kamei

Journal of Fungi, 2021

View PDFchevron_right

Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections

Sachin Deorukhkar

Infectious Disorders - Drug Targets, 2016

View PDFchevron_right

Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

David Perlin

Antimicrobial Agents and Chemotherapy, 2011

View PDFchevron_right

Breakthrough Invasive Candidiasis in Patients on Micafungin

David Perlin

Journal of Clinical Microbiology, 2010

View PDFchevron_right

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

David Facklam

Alimentary Pharmacology & Therapeutics, 2004

View PDFchevron_right

Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

M. Uzunov

European Journal of Clinical Microbiology & Infectious Diseases, 2014

View PDFchevron_right

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

David Facklam

European Journal of Clinical Microbiology & Infectious Diseases, 2006

View PDFchevron_right

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis (original) (raw)

Related papers